A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design

被引:4
作者
Hizawa, Nobuyuki [1 ]
Fukunaga, Koichi [2 ]
Sugiura, Hisatoshi [3 ]
Nakano, Yasutaka [4 ]
Kato, Motokazu [5 ]
Sugiyama, Yutaro [6 ]
Hanazawa, Tomohiro [6 ]
Kaise, Toshihiko [6 ]
Tal-Singer, Ruth [7 ]
Jones, Paul W. [8 ]
Barnes, Neil [8 ,9 ]
Compton, Chris [8 ]
Ishii, Takeo [6 ]
机构
[1] Univ Tsukuba, Fac Med, Dept Pulm Med, Tsukuba, Ibaraki, Japan
[2] Keio Univ, Dept Med, Pulm Div, Sch Med, Tokyo, Japan
[3] Tohoku Univ, Dept Resp Med, Grad Sch Med, Sendai, Miyagi, Japan
[4] Shiga Univ Med Sci, Dept Internal Med, Div Resp Med, Otsu, Shiga, Japan
[5] Kamei Hosp, Resp Inst, Osaka, Japan
[6] GSK KK, Resp Med Affair & Dev, Tokyo, Japan
[7] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[8] GSK, Brentford, Middx, England
[9] Barts & London Queen Marys Sch Med & Dent, London, England
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2021年 / 16卷
关键词
ACO; asthma; COPD; personalized medicine; biomarkers; treatable traits; CLINICAL-FEATURES; COPD; ASTHMA; MEDICINE; ECLIPSE;
D O I
10.2147/COPD.S308327
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) are complex and heterogeneous diseases that share clinical characteristics (phenotypes) and molecular mechanisms (endotypes). Whilst physicians make clinical decisions on diagnostic groups, for some such as ACO there is no commonly accepted criteria. An alternative approach is to evaluate phenotypes and endotypes that are considered to respond well to a specific type of treatment ("treatable traits") rather than diagnostic labels. Purpose: The prospective, longitudinal, and observational TRAIT study will evaluate disease characteristics, including both phenotypes and endotypes, in relation to the presentation of obstructive respiratory disease characteristics in patients diagnosed with asthma, COPD, or ACO in Japan, with the aim of further understanding the clinical benefit of a treatable traits-based approach. Patients and Methods: A total of 1500 participants will be enrolled into three cohorts according to their treating physician's diagnosis of asthma, COPD, or ACO at screening. Part 1 of the study will involve cross-sectional phenotyping and endotyping at study enrollment. Part 2 of the study will evaluate the progression of clinical characteristics, biomarker profiles, and treatment over a 3-year follow-up period. The follow-up will involve three annual study visits and three telephone calls scheduled at 6-month intervals. A substudy involving 50 participants from the asthma cohort (in which the ratio will be approximately 1:1 including 25 participants with a smoking history of >= 10 pack-years and 25 participants with no smoking history), 100 participants from the ACO cohort, and 100 participants from the COPD cohort will evaluate disease phenotypes using inspiratory and expiratory computed tomography scans. Conclusion: TRAIT will describe clinical characteristics of patients with obstructive respiratory diseases to better understand potential differences and similarities between clinical diagnoses, which will support the improvement of personalized treatment strategies.
引用
收藏
页码:1813 / 1822
页数:10
相关论文
共 40 条
[1]   Treatable traits: toward precision medicine of chronic airway diseases [J].
Agusti, Alvar ;
Bel, Elisabeth ;
Thomas, Mike ;
Vogelmeier, Claus ;
Brusselle, Guy ;
Holgate, Stephen ;
Humbert, Marc ;
Jones, Paul ;
Gibson, Peter G. ;
Vestbo, Jorgen ;
Beasley, Richard ;
Pavord, Ian D. .
EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (02) :410-419
[2]   The path to personalised medicine in COPD [J].
Agusti, Alvar .
THORAX, 2014, 69 (09) :857-864
[3]   The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world [J].
Barnes, Neil ;
Ishii, Takeo ;
Hizawa, Nobuyuki ;
Midwinter, Dawn ;
James, Mark ;
Hilton, Emma ;
Jones, Paul W. .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 :433-440
[4]   The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? [J].
Bateman, Eric D. ;
Reddel, Helen K. ;
van Zyl-Smit, Richard N. ;
Agusti, Alvar .
LANCET RESPIRATORY MEDICINE, 2015, 3 (09) :719-728
[5]   Defining asthma-COPD overlap syndrome: a population-based study [J].
Bonten, Tobias N. ;
Kasteleyn, Marise J. ;
de Mutsert, Renee ;
Hiemstra, Pieter S. ;
Rosendaal, Frits R. ;
Chavannes, Niels H. ;
Slats, Annelies M. ;
Taube, Christian .
EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
[6]  
ClinialTrials.gov, PROSP COH STUD ASTHM
[7]  
ClinialTrials.jp, 2019, OBSTR RESP DIS PHEN
[8]   Asthma-COPD overlap: identification and optimal treatment [J].
Cosio, Borja G. ;
Dacal, David ;
Perez de Llano, Luis .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
[9]   Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) [J].
Couper, David ;
LaVange, Lisa M. ;
Han, MeiLan ;
Barr, R. Graham ;
Bleecker, Eugene ;
Hoffman, Eric A. ;
Kanner, Richard ;
Kleerup, Eric ;
Martinez, Fernando J. ;
Woodruff, Prescott G. ;
Rennard, Stephen .
THORAX, 2014, 69 (05) :491-494
[10]   Lessons from ECLIPSE: a review of COPD biomarkers [J].
Faner, Rosa ;
Tal-Singer, Ruth ;
Riley, John H. ;
Celli, Bartolome ;
Vestbo, Jorgen ;
MacNee, William ;
Bakke, Per ;
Calverley, Peter M. A. ;
Coxson, Harvey ;
Crim, Courtney ;
Edwards, Lisa D. ;
Locantore, Nick ;
Lomas, David A. ;
Miller, Bruce E. ;
Rennard, Stephen I. ;
Wouters, Emiel F. M. ;
Yates, Julie C. ;
Silverman, Edwin K. ;
Agusti, Alvar .
THORAX, 2014, 69 (07) :666-672